Georgia is currently home to 1974 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Atlanta, Augusta, Decatur and Savannah. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)
Recruiting
A study to assess the safety, tolerability, and PK of tarlatamab in participants with SCLC
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Winship Cancer Institute, Atlanta, Georgia
Conditions: Small Cell Lung Carcinoma
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Recruiting
This is a global, multicenter, open-label safety extension study. Participants receiving single-agent trastuzumab emtansine or trastuzumab emtansine administered in combination with other anti-cancer therapies in a Genentech / Roche-sponsored parent study who are active and receiving benefit at the closure of parent study are eligible for continued treatment in this study.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Northwest Georgia Oncology Centers PC - Marietta, Marietta, Georgia
Conditions: Neoplasm Metastasis
Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (BMS-986446) in Participants With Early Alzheimer's Disease
Recruiting
The purpose of this study is to assess the effectiveness, safety, and tolerability of BMS-986446 an Anti-MTBR Tau Monoclonal Antibody in participants with Early Alzheimer's Disease.
Gender:
All
Ages:
Between 50 years and 80 years
Trial Updated:
03/26/2024
Locations: Columbus Memory Center, Columbus, Georgia
Conditions: Alzheimer Disease, Early Onset
A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF
Recruiting
The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/26/2024
Locations: Georgia Arrhythmia Consultants and Research Institute, Macon, Georgia
Conditions: Drug Refractory Paroxysmal Atrial Fibrillation
A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Recruiting
The purpose of the study is to see how effective JNJ-77242113 is in participants with moderate to severe plaque psoriasis compared to placebo and deucravacitinib.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Hamilton Research, LLC., Alpharetta, Georgia
Conditions: Plaque Psoriasis
A Study of JNJ-77242113 in Adolescent and Adult Participants With Moderate to Severe Plaque Psoriasis
Recruiting
The purpose of this study is see how effective is JNJ-77242113 in participants with moderate to severe plaque psoriasis.
Gender:
All
Ages:
12 years and above
Trial Updated:
03/26/2024
Locations: Skin Care Physicians of Georgia, Macon, Georgia
Conditions: Plaque Psoriasis
Evaluation of Safety, Immunogenicity and Efficacy of a Triple Immune Regimen in Adults Initiated on ART During Acute HIV-1
Recruiting
The purpose of this study is to evaluate the safety, tolerability, and efficacy of therapeutic vaccination with chimpanzee adenovirus (ChAdV)- and poxvirus modified vaccinia Ankara (MVA)-vectored conserved mosaic T-cell vaccines in a sequential regimen with the Toll-like Receptor 7 (TLR7) agonist vesatolimod (VES) and two broadly neutralizing antibodies (bNAbs) compared to placebo, to induce HIV-1 control during analytic treatment interruption (ATI).
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Ponce de Leon Center CRS, Atlanta, Georgia
Conditions: HIV-1-infection
A Study of JNJ-77242113 in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of JNJ-77242113 compared with placebo in participants with moderately to severely active ulcerative colitis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Atlanta Gastroenterology Associates, Atlanta, Georgia
Conditions: Colitis, Ulcerative
A Study to Assess Change in Disease Activity, Adverse Events, and How the Drug Moves Through the Body in Adult Participants Living With Human Immunodeficiency Virus (HIV) Receiving Intravenous (IV) Infusion of Budigalimab and/or ABBV-382
Recruiting
Human immuno-deficiency virus (HIV) is the virus that causes Acquired Immuno-Deficiency Syndrome (AIDS). HIV disease is considered to be a chronic disease requiring lifelong therapy. The purpose of this study is to assess change in disease activity, adverse events, tolerability, and how the drug moves through the body. Budigalimab and ABBV-382 are investigational drugs being developed for the treatment of HIV disease. Participants are placed in 1 of 5 groups, called treatment arms. Each group r... Read More
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/26/2024
Locations: Infectious Disease Specialists of Atlanta /ID# 256955, Decatur, Georgia
Conditions: Human Immuno-deficiency Virus (HIV) Disease
Study to Assess the Safety and Efficacy of Subcutaneously Injected Risankizumab in Adult Participants With Genital or Scalp Psoriasis
Recruiting
Psoriasis (PsO) is a chronic disease characterized by marked inflammation of the skin that results in thick, red, scaly plaques. This study will assess how safe and effective risankizumab is in adult participants with moderate to severe genital psoriasis or moderate to severe scalp psoriasis. Adverse events and change in disease signs and symptoms will be monitored. Risankizumab (Skyrizi) is a drug being studied for the treatment of moderate to severe genital psoriasis or moderate to severe sca... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: Hamilton Research, LLC /ID# 255409, Alpharetta, Georgia
Conditions: Genital Psoriasis, Scalp Psoriasis
A Study to Evaluate Intravitreal JNJ-81201887 (AAVCAGsCD59) Compared to Sham Procedure for the Treatment of Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
Recruiting
The purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Gender:
All
Ages:
60 years and above
Trial Updated:
03/26/2024
Locations: Georgia Retina, Marietta, Georgia
Conditions: Geographic Atrophy
Peer Interventions for Preschoolers With Autism
Recruiting
This proposal will evaluate a series of peer-mediated interventions (PMIs) for preschool children (3 to 6 years) with ASD and limited or no spoken language, using an innovative Sequential Multiple Assignment Randomized Trial (SMART) design. Available evidence supports the beneficial effects of PMIs for improving social communication in children with ASD. Peer-related social competence is vital to a wide range of child outcomes, such as improved communication and fewer behavioral problems. Unfort... Read More
Gender:
All
Ages:
Between 3 years and 6 years
Trial Updated:
03/26/2024
Locations: Juniper Gardens Children's Project, Kansas City, Kansas
Conditions: Autism Spectrum Disorder